FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

For the month of December 2025 

 

Commission File Number: 001-11960

 

AstraZeneca PLC

 

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

 

 

AstraZeneca PLC

 

INDEX TO EXHIBITS

 

 

 19 December 2025

 

 

Transaction by Person Discharging Managerial Responsibilities and Person Closely Associated

 

 

AstraZeneca PLC (the Company) announces that, on 17 December 2025, it was notified by Philip Broadley, Non-Executive Director, that on 17 December 2025, Mr Broadley gifted 5,735 ordinary shares of $0.25 each in the Company, for nil consideration, to his spouse, who is a person closely associated (PCA) to Mr Broadley.  

 

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Philip Broadley
2	Reason for the notification
a)	Position/status	Non-Executive Director and PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument   Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC   GB0009895292
b)	Nature of the transaction	Gift of shares for nil consideration
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		0	5,735
d)	Aggregated information   - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	17 December 2025
f)	Place of the transaction	Outside a trading venue

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Gillian Broadley
2	Reason for the notification
a)	Position/status	Person Closely Associated (PCA) to Philip Broadley (PDMR)
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument   Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC   GB0009895292
b)	Nature of the transaction	Receipt of gift of shares for nil consideration
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		0	5,735
d)	Aggregated information   - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	17 December 2025
f)	Place of the transaction	Outside a trading venue

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on social media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

 

Date: 19 December 2025

	By: /s/ Matthew Bowden
	Name: Matthew Bowden
	Title: Company Secretary